恒瑞医药:公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市

证券日报
Feb 11

  证券日报网讯 2月11日,恒瑞医药在互动平台回答投资者提问时表示,公司坚持差异化研发策略,以临床需求为导向,利用领先的技术平台打造差异化创新产品矩阵。例如,公司自主研发的1类创新药瑞拉芙普α注射液已于2026年1月在国内获批上市,是全球首款获批上市的抗PD-L1/TGF-βRII双特异性抗体融合蛋白;公司还有100多个自主创新产品正在临床开发,其中不乏具有同类首创/同类最佳潜力的产品。公司未来还将继续积极探索国际前沿的、具有同类首创或同类最佳潜力的药物靶点,不断产出差异化、具有创新竞争力的产品。

(文章来源:证券日报)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10